Martínez Ríos: “SOLACI Went from a Dream to a World-Renowned Society”

Dr. Marco Antonio Martínez Ríos comes from a family of physicians. “Studying Medicine was the most natural thing in the world for me,” admits Martínez Ríos, who in 1993 became president of the Latin American Group of Interventional Cardiology (Grupo Latinoamericano de Cardiología Intervencionista, GLACI), the seed that would grow to become SOLACI in 1994.  <a href="https://solaci.org/en/2016/09/27/martinez-rios-solaci-went-from-a-dream-to-a-world-renowned-society/" title="Read more" >...</a>

Prasugrel vs. Ticagrelor in Diabetics with Heart Disease

Diabetic patients are increased risk of thrombotic events, which is why an effective antiplatelet therapy is crucial for these patients. Both prasugrel and ticagrelor have shown to reduce thrombotic complications further than clopidogrel.   Subgroup analyzes of the most important studies testing prasugrel and ticagrelor vs. clopidogrel have shown that diabetic patients receiving the new<a href="https://solaci.org/en/2016/09/23/prasugrel-vs-ticagrelor-in-diabetics-with-heart-disease/" title="Read more" >...</a>

bifurcaciones tap o culotte provisional stenting

Culotte vs. TAP in Bifurcations: Which is Better?

Courtesy of Dr. Agustín Vecchia.   In treating bifurcations, the provisional stenting strategy continues to be preferred. However, a percentage of these lesions must be treated with two stents, which involves different techniques. In provisional stenting, when two stents are required, a recent consensus document of the European Bifurcation Club has recently recommended the TAP<a href="https://solaci.org/en/2016/09/14/culotte-vs-tap-in-bifurcations-which-is-better/" title="Read more" >...</a>

reducir costos ffr inducido por contraste

Contrast Induced FFR: Cost and Time Effective Alternative

Courtesy of Dr. Guillermo Migliaro.   Fractional flow reserve (FFR) is the radio of two flows expressed as the ratio of two pressures ─ distal pressure across stenosis (Pd) to aortic pressure (pa) ─ obtained only under maximal coronary hyperemia, which is a state of drug induced maximal vasodilation.   The gold standard to create<a href="https://solaci.org/en/2016/09/12/contrast-induced-ffr-cost-and-time-effective-alternative/" title="Read more" >...</a>

Xience V: Safe in “Real-Life” Bifurcation Lesions

Courtesy of Dr. Rodrigo Abreu.   INTRODUCTION Bifurcation lesion treatment has evolved considerably in the last years: from balloon angioplasty (with high occlusion and restenosis rates) to bare metal stent angioplasty (with a procedural success around 86% and major adverse cardiac events [MACE] at 1 year around 32%). The subsequent emergence of drug-eluting stents (DES) reduced<a href="https://solaci.org/en/2016/09/09/xience-v-safe-in-real-life-bifurcation-lesions/" title="Read more" >...</a>

Angiosome: Is It Feasible in Critical Limb Ischemia?

Courtesy of Dr. Carlos Fava.   Critical limb ischemia (CLI) accompanied by tissue loss entails high risk of amputation. At present, there is substantial evidence in favor of revascularization by PCI according to the angiosome concept, but the feasibility of this treatment remains unclear.   161 compromised limbs were analyzed in 160 patients with foot<a href="https://solaci.org/en/2016/09/02/angiosome-is-it-feasible-in-critical-limb-ischemia/" title="Read more" >...</a>

Coronary Perforation in PCI: Associated to Negative Outcomes

Courtesy of Dr. Guillermo Migliaro.   Coronary perforation (CP) is a rare but serious complication of percutaneous coronary intervention (PCI) with an estimated incidence of 0.5%. Arterial blood entering the pericardium may cause a rapid elevation of intrapericardial pressure and collapse the right cavities (tamponade) creating hemodynamic compromise.   Historically, surgical drainage has been the<a href="https://solaci.org/en/2016/08/31/coronary-perforation-in-pci-associated-to-negative-outcomes/" title="Read more" >...</a>

Beta-Blockers for Revascularized Patients: To Prescribe or Not?

This study examines predictors and outcomes associated with the prescription of beta-blockers at discharge after a successful coronary angioplasty in patients with stable chronic angina WITHOUT prior history of acute myocardial infarction or heart failure.   The benefit of beta-blockers in patients with acute myocardial infarction or systolic heart failure is well documented. However, their<a href="https://solaci.org/en/2016/08/23/beta-blockers-for-revascularized-patients-to-prescribe-or-not/" title="Read more" >...</a>

cangrelor vs. clopidogrel infartos peri-procedimiento

Peri-Procedural MI Reduction: Cangrelor or Clopidogrel?

Cangrelor is an intravenous P2Y12 inhibitor approved to reduce peri-procedural ischemic events in patients undergoing PCI that have not previously received any other P2Y12 inhibitor.   The CHAMPION PHOENIX trial randomized a total of 11,145 patients to cangrelor vs. clopidogrel.   The study sought to explore the effect of cangrelor on peri-procedural acute myocardial infarction<a href="https://solaci.org/en/2016/08/22/peri-procedural-mi-reduction-cangrelor-or-clopidogrel/" title="Read more" >...</a>

Optimal Duration of DAPT: How to Predict Long-Term Events

Courtesy of Dr. Santiago F. Coroleu.   Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after percutaneous coronary intervention (PCI) reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB). However, the lack of information to accurately predict the occurrence of each event in out-of-hospital patients under<a href="https://solaci.org/en/2016/08/17/optimal-duration-of-dapt-how-to-predict-long-term-events/" title="Read more" >...</a>

left main